Phase I study of nintedanib in Japanese patients with advanced hepatocellular carcinoma and liver impairment

This phase I, dose‐escalation study evaluated the safety, preliminary efficacy and pharmacokinetics of nintedanib, a triple angiokinase inhibitor, in Japanese patients with advanced hepatocellular carcinoma and mild/moderate liver impairment. Thirty patients with unresectable hepatocellular carcinom...

Descripción completa

Detalles Bibliográficos
Autores principales: Okusaka, Takuji, Otsuka, Taiga, Ueno, Hideki, Mitsunaga, Shuichi, Sugimoto, Rie, Muro, Kei, Saito, Isao, Tadayasu, Yusuke, Inoue, Kohei, Loembé, Arsene‐Bienvenu, Ikeda, Masafumi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198968/
https://www.ncbi.nlm.nih.gov/pubmed/27627050
http://dx.doi.org/10.1111/cas.13077

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5198968/
https://www.ncbi.nlm.nih.gov/pubmed/27627050
http://dx.doi.org/10.1111/cas.13077

Ejemplares similares